Tg(Eef1a1-MYC/PGR*,-HRAS/ESR1*)1Rdl

The human MYC and (mutant) HRAS oncogenes can be conditionally expressed from this transgene, and activity of either or both proteins can be induced. The transgene contains the promoter of the ubiquitously expressed eukaryotic translation elongation factor 1 alpha 1 (Eef1a1) gene followed by: a loxP-flanked STOP sequence; a cDNA encoding the human v-myc avian myelocytomatosis viral oncogene homolog (MYC) protein fused to a mutated ligand-binding domain of the human progesterone receptor (hPR891) that binds to mifepristone (RU486), but not to endogenous progesterone; an internal ribosomal entry site (IRES); and a cDNA encoding the oncogenic G12V (glycine to valine at amino acid position 12) mutant human HRAS protein fused to a mutated estrogen receptor binding domain that binds to tamoxifen, but not to endogenous estrogen. Crossing mice bearing this transgene with mice expressing Cre recombinase will delete the STOP sequence, allowing transcription to proceed in the tissues or cell types where Cre is expressed. Treatment of the doubly transgenic mice with RU486 and/or tamoxifen will then activate the MYC and/or mutant HRAS protein, respectively, in those tissues/cell types. (J:227110)